Cargando…

Epidermal Growth Factor Receptor Tyrosine Kinase Defines Critical Prognostic Genes of Stage I Lung Adenocarcinoma

PURPOSE: To identify stage I lung adenocarcinoma patients with a poor prognosis who will benefit from adjuvant therapy. PATIENTS AND METHODS: Whole gene expression profiles were obtained at 19 time points over a 48-hour time course from human primary lung epithelial cells that were stimulated with e...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamauchi, Mai, Yamaguchi, Rui, Nakata, Asuka, Kohno, Takashi, Nagasaki, Masao, Shimamura, Teppei, Imoto, Seiya, Saito, Ayumu, Ueno, Kazuko, Hatanaka, Yousuke, Yoshida, Ryo, Higuchi, Tomoyuki, Nomura, Masaharu, Beer, David G., Yokota, Jun, Miyano, Satoru, Gotoh, Noriko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446964/
https://www.ncbi.nlm.nih.gov/pubmed/23028479
http://dx.doi.org/10.1371/journal.pone.0043923
_version_ 1782244050281168896
author Yamauchi, Mai
Yamaguchi, Rui
Nakata, Asuka
Kohno, Takashi
Nagasaki, Masao
Shimamura, Teppei
Imoto, Seiya
Saito, Ayumu
Ueno, Kazuko
Hatanaka, Yousuke
Yoshida, Ryo
Higuchi, Tomoyuki
Nomura, Masaharu
Beer, David G.
Yokota, Jun
Miyano, Satoru
Gotoh, Noriko
author_facet Yamauchi, Mai
Yamaguchi, Rui
Nakata, Asuka
Kohno, Takashi
Nagasaki, Masao
Shimamura, Teppei
Imoto, Seiya
Saito, Ayumu
Ueno, Kazuko
Hatanaka, Yousuke
Yoshida, Ryo
Higuchi, Tomoyuki
Nomura, Masaharu
Beer, David G.
Yokota, Jun
Miyano, Satoru
Gotoh, Noriko
author_sort Yamauchi, Mai
collection PubMed
description PURPOSE: To identify stage I lung adenocarcinoma patients with a poor prognosis who will benefit from adjuvant therapy. PATIENTS AND METHODS: Whole gene expression profiles were obtained at 19 time points over a 48-hour time course from human primary lung epithelial cells that were stimulated with epidermal growth factor (EGF) in the presence or absence of a clinically used EGF receptor tyrosine kinase (RTK)-specific inhibitor, gefitinib. The data were subjected to a mathematical simulation using the State Space Model (SSM). “Gefitinib-sensitive” genes, the expressional dynamics of which were altered by addition of gefitinib, were identified. A risk scoring model was constructed to classify high- or low-risk patients based on expression signatures of 139 gefitinib-sensitive genes in lung cancer using a training data set of 253 lung adenocarcinomas of North American cohort. The predictive ability of the risk scoring model was examined in independent cohorts of surgical specimens of lung cancer. RESULTS: The risk scoring model enabled the identification of high-risk stage IA and IB cases in another North American cohort for overall survival (OS) with a hazard ratio (HR) of 7.16 (P = 0.029) and 3.26 (P = 0.0072), respectively. It also enabled the identification of high-risk stage I cases without bronchioalveolar carcinoma (BAC) histology in a Japanese cohort for OS and recurrence-free survival (RFS) with HRs of 8.79 (P = 0.001) and 3.72 (P = 0.0049), respectively. CONCLUSION: The set of 139 gefitinib-sensitive genes includes many genes known to be involved in biological aspects of cancer phenotypes, but not known to be involved in EGF signaling. The present result strongly re-emphasizes that EGF signaling status in cancer cells underlies an aggressive phenotype of cancer cells, which is useful for the selection of early-stage lung adenocarcinoma patients with a poor prognosis. TRIAL REGISTRATION: The Gene Expression Omnibus (GEO) GSE31210
format Online
Article
Text
id pubmed-3446964
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-34469642012-10-01 Epidermal Growth Factor Receptor Tyrosine Kinase Defines Critical Prognostic Genes of Stage I Lung Adenocarcinoma Yamauchi, Mai Yamaguchi, Rui Nakata, Asuka Kohno, Takashi Nagasaki, Masao Shimamura, Teppei Imoto, Seiya Saito, Ayumu Ueno, Kazuko Hatanaka, Yousuke Yoshida, Ryo Higuchi, Tomoyuki Nomura, Masaharu Beer, David G. Yokota, Jun Miyano, Satoru Gotoh, Noriko PLoS One Research Article PURPOSE: To identify stage I lung adenocarcinoma patients with a poor prognosis who will benefit from adjuvant therapy. PATIENTS AND METHODS: Whole gene expression profiles were obtained at 19 time points over a 48-hour time course from human primary lung epithelial cells that were stimulated with epidermal growth factor (EGF) in the presence or absence of a clinically used EGF receptor tyrosine kinase (RTK)-specific inhibitor, gefitinib. The data were subjected to a mathematical simulation using the State Space Model (SSM). “Gefitinib-sensitive” genes, the expressional dynamics of which were altered by addition of gefitinib, were identified. A risk scoring model was constructed to classify high- or low-risk patients based on expression signatures of 139 gefitinib-sensitive genes in lung cancer using a training data set of 253 lung adenocarcinomas of North American cohort. The predictive ability of the risk scoring model was examined in independent cohorts of surgical specimens of lung cancer. RESULTS: The risk scoring model enabled the identification of high-risk stage IA and IB cases in another North American cohort for overall survival (OS) with a hazard ratio (HR) of 7.16 (P = 0.029) and 3.26 (P = 0.0072), respectively. It also enabled the identification of high-risk stage I cases without bronchioalveolar carcinoma (BAC) histology in a Japanese cohort for OS and recurrence-free survival (RFS) with HRs of 8.79 (P = 0.001) and 3.72 (P = 0.0049), respectively. CONCLUSION: The set of 139 gefitinib-sensitive genes includes many genes known to be involved in biological aspects of cancer phenotypes, but not known to be involved in EGF signaling. The present result strongly re-emphasizes that EGF signaling status in cancer cells underlies an aggressive phenotype of cancer cells, which is useful for the selection of early-stage lung adenocarcinoma patients with a poor prognosis. TRIAL REGISTRATION: The Gene Expression Omnibus (GEO) GSE31210 Public Library of Science 2012-09-19 /pmc/articles/PMC3446964/ /pubmed/23028479 http://dx.doi.org/10.1371/journal.pone.0043923 Text en © 2012 Yamauchi et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Yamauchi, Mai
Yamaguchi, Rui
Nakata, Asuka
Kohno, Takashi
Nagasaki, Masao
Shimamura, Teppei
Imoto, Seiya
Saito, Ayumu
Ueno, Kazuko
Hatanaka, Yousuke
Yoshida, Ryo
Higuchi, Tomoyuki
Nomura, Masaharu
Beer, David G.
Yokota, Jun
Miyano, Satoru
Gotoh, Noriko
Epidermal Growth Factor Receptor Tyrosine Kinase Defines Critical Prognostic Genes of Stage I Lung Adenocarcinoma
title Epidermal Growth Factor Receptor Tyrosine Kinase Defines Critical Prognostic Genes of Stage I Lung Adenocarcinoma
title_full Epidermal Growth Factor Receptor Tyrosine Kinase Defines Critical Prognostic Genes of Stage I Lung Adenocarcinoma
title_fullStr Epidermal Growth Factor Receptor Tyrosine Kinase Defines Critical Prognostic Genes of Stage I Lung Adenocarcinoma
title_full_unstemmed Epidermal Growth Factor Receptor Tyrosine Kinase Defines Critical Prognostic Genes of Stage I Lung Adenocarcinoma
title_short Epidermal Growth Factor Receptor Tyrosine Kinase Defines Critical Prognostic Genes of Stage I Lung Adenocarcinoma
title_sort epidermal growth factor receptor tyrosine kinase defines critical prognostic genes of stage i lung adenocarcinoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446964/
https://www.ncbi.nlm.nih.gov/pubmed/23028479
http://dx.doi.org/10.1371/journal.pone.0043923
work_keys_str_mv AT yamauchimai epidermalgrowthfactorreceptortyrosinekinasedefinescriticalprognosticgenesofstageilungadenocarcinoma
AT yamaguchirui epidermalgrowthfactorreceptortyrosinekinasedefinescriticalprognosticgenesofstageilungadenocarcinoma
AT nakataasuka epidermalgrowthfactorreceptortyrosinekinasedefinescriticalprognosticgenesofstageilungadenocarcinoma
AT kohnotakashi epidermalgrowthfactorreceptortyrosinekinasedefinescriticalprognosticgenesofstageilungadenocarcinoma
AT nagasakimasao epidermalgrowthfactorreceptortyrosinekinasedefinescriticalprognosticgenesofstageilungadenocarcinoma
AT shimamurateppei epidermalgrowthfactorreceptortyrosinekinasedefinescriticalprognosticgenesofstageilungadenocarcinoma
AT imotoseiya epidermalgrowthfactorreceptortyrosinekinasedefinescriticalprognosticgenesofstageilungadenocarcinoma
AT saitoayumu epidermalgrowthfactorreceptortyrosinekinasedefinescriticalprognosticgenesofstageilungadenocarcinoma
AT uenokazuko epidermalgrowthfactorreceptortyrosinekinasedefinescriticalprognosticgenesofstageilungadenocarcinoma
AT hatanakayousuke epidermalgrowthfactorreceptortyrosinekinasedefinescriticalprognosticgenesofstageilungadenocarcinoma
AT yoshidaryo epidermalgrowthfactorreceptortyrosinekinasedefinescriticalprognosticgenesofstageilungadenocarcinoma
AT higuchitomoyuki epidermalgrowthfactorreceptortyrosinekinasedefinescriticalprognosticgenesofstageilungadenocarcinoma
AT nomuramasaharu epidermalgrowthfactorreceptortyrosinekinasedefinescriticalprognosticgenesofstageilungadenocarcinoma
AT beerdavidg epidermalgrowthfactorreceptortyrosinekinasedefinescriticalprognosticgenesofstageilungadenocarcinoma
AT yokotajun epidermalgrowthfactorreceptortyrosinekinasedefinescriticalprognosticgenesofstageilungadenocarcinoma
AT miyanosatoru epidermalgrowthfactorreceptortyrosinekinasedefinescriticalprognosticgenesofstageilungadenocarcinoma
AT gotohnoriko epidermalgrowthfactorreceptortyrosinekinasedefinescriticalprognosticgenesofstageilungadenocarcinoma